Targeted treatment of mutated EGFR-expressing non-small-cell lung cancer: focus on erlotinib with companion diagnostics

Código QR

Targeted treatment of mutated EGFR-expressing non-small-cell lung cancer: focus on erlotinib with companion diagnostics

Niki Karachaliou,1 Rafael Rosell21Translational Research Unit, Dr Rosell Oncology Institute, Quirón Dexeus University Hospital, 2Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Barcelona, SpainAbstract: Deeper understanding of...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Karachaliou N, Rosell R
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/77c44333ddb0431eb1435fdb26c5db4c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Targeted Treatment of Non-Small Cell Lung Cancer: Focus on Capmatinib with Companion Diagnostics
por: Guo MZ, et al.
Publicado: (2021)

Development of personalized treatments in lung cancer: focusing on the EGFR mutations and beyond
por: Suda K, et al.
Publicado: (2013)

Correction: Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations
Publicado: (2021)

Economic evaluation of pemetrexed versus erlotinib as second-line treatment of patients with advanced/metastatic non-small cell lung cancer in Greece: a cost minimization analysis
por: Fragoulakis VF, et al.
Publicado: (2012)

The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer
por: Barbara Melosky, et al.
Publicado: (2021)

Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR
por: Karan Seegobin, et al.
Publicado: (2021)

Non-small cell lung cancer: the era of targeted therapy
por: Antonoff MB, et al.
Publicado: (2012)

Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity
por: Takahiro Yoshizawa, et al.
Publicado: (2021)

Targeting PD-1/PD-L1 in lung cancer: current perspectives
por: González-Cao M, et al.
Publicado: (2015)

Epiregulin as a therapeutic target in non-small-cell lung cancer
por: Sunaga N, et al.
Publicado: (2015)

Prevalence of driver mutations in non-small-cell lung cancers in the People’s Republic of China
por: Gou LY, Wu YL
Publicado: (2014)

Targeting MERTK and AXL in <i>EGFR</i> Mutant Non-Small Cell Lung Cancer
por: Dan Yan, et al.
Publicado: (2021)

Combined FGFR and Akt pathway inhibition abrogates growth of FGFR1 overexpressing EGFR-TKI-resistant NSCLC cells
por: Mikkel G. Terp, et al.
Publicado: (2021)

EGFR mutations in patients with lung adenocarcinoma in southwest China: are G719S/A and L861Q more likely detected in tumors derived from smokers?
por: Wang QS, et al.
Publicado: (2013)

A Prospective Observational Study of Osimertinib for Chemo-Naive Elderly Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer
por: Igawa S, et al.
Publicado: (2021)

Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study
por: Taichi Miyawaki, et al.
Publicado: (2021)

Afatinib treatment in advanced non-small cell lung cancer
por: Hurwitz JL, et al.
Publicado: (2011)

Computer extracted gland features from H&E predicts prostate cancer recurrence comparably to a genomic companion diagnostic test: a large multi-site study
por: Patrick Leo, et al.
Publicado: (2021)

Emerging treatment options in the management of non-small cell lung cancer
por: Filosso PL, et al.
Publicado: (2011)

Non-small-cell lung carcinoma: role of the Notch signaling pathway
por: Barse L, et al.
Publicado: (2015)

Pemetrexed in maintenance treatment of advanced non-squamous non-small-cell lung cancer
por: Minami S, et al.
Publicado: (2015)

A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer
por: Natalia J. Gurule, et al.
Publicado: (2021)

Profile of bavituximab and its potential in the treatment of non-small-cell lung cancer
por: Stasi I, et al.
Publicado: (2014)

Profile of ceritinib in the treatment of ALK+ metastatic non-small-cell lung cancer
por: Burns MW, et al.
Publicado: (2015)

Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient
por: Maurício Fernando Silva Almeida Ribeiro, et al.
Publicado: (2021)

Construction of a circRNA-miRNA-mRNA Regulated Pathway Involved in EGFR-TKI Lung Adenocarcinoma Resistance
por: Chenyue Dai MM, et al.
Publicado: (2021)

Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy
por: Santarpia M, et al.
Publicado: (2017)

First-line treatment of advanced ALK-positive non-small-cell lung cancer
por: Gandhi S, et al.
Publicado: (2015)

New options in the management of intractable ALK(+) metastatic non-small-cell lung cancer
por: Weise AM, et al.
Publicado: (2014)

Impact of smoking on frequency and spectrum of K-RAS and EGFR mutations in treatment naive Indonesian lung cancer patients
por: Masykura N, et al.
Publicado: (2019)

Treatment patterns, testing practices, and outcomes in the pre-FLAURA era for patients with EGFR mutation-positive advanced NSCLC: a retrospective chart review (REFLECT)
por: Alfredo Addeo, et al.
Publicado: (2021)

Combination chemotherapy of gemcitabine and vinorelbine for pretreated non-small- cell lung cancer: a retrospective study
por: Minami S, et al.
Publicado: (2015)

Anaplastic lymphoma kinase (ALK) inhibitors for second-line therapy of non-small cell lung cancer
por: Berghmans T, et al.
Publicado: (2012)

An Observational Study to Assess the Molecular Epidemiology and Direct Medical Costs of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer Treated with Afatinib in Real-World Clinical Settings in Greece
por: Mountzios G, et al.
Publicado: (2021)

Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis
por: Kate S, et al.
Publicado: (2019)

Clinical potential of nintedanib for the second-line treatment of advanced non-small-cell lung cancer: current evidence
por: Rothschild SI
Publicado: (2014)

Clinical characteristics and outcomes of Chinese patients with KRAS‐mutant non‐small cell lung cancer after chemotherapy
por: Yawen Zheng, et al.
Publicado: (2021)

Response to rapamycin analogs but not PD-1 inhibitors in PTEN-mutated metastatic non-small-cell lung cancer with high tumor mutational burden
por: Parikh AR, et al.
Publicado: (2018)

Osimertinib in Combination with Bevacizumab Fails in Advanced Lung Adenocarcinoma Harboring EGFR T790M
por: Xiaoying Zhang
Publicado: (2021)

Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer
por: Takeda M, et al.
Publicado: (2011)